193 related articles for article (PubMed ID: 6117927)
1. [Abnormalities of catecholamine metabolism in Parkinson's disease (author's transl)].
Nagatsu T
Tanpakushitsu Kakusan Koso; 1981 Aug; 26(11):1781-8. PubMed ID: 6117927
[No Abstract] [Full Text] [Related]
2. Parkinson's disease: from brain homogenate to treatment.
Hornykiewicz O
Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
[No Abstract] [Full Text] [Related]
3. [Parkinson's disease].
Nagatsu T
Tanpakushitsu Kakusan Koso; 1984 Dec; 29(14):1801-14. PubMed ID: 6152497
[No Abstract] [Full Text] [Related]
4. Catecholamine-related enzymes and the biopterin cofactor in Parkinson's disease and related extrapyramidal diseases.
Nagatsu T; Yamaguchi T; Rahman MK; Trocewicz J; Oka K; Hirata Y; Nagatsu I; Narabayashi H; Kondo T; Iizuka R
Adv Neurol; 1984; 40():467-73. PubMed ID: 6141712
[TBL] [Abstract][Full Text] [Related]
5. [Biochemical bases of Parkinson disease].
Colucci d'Amato C; Puccini A; Cristillo A; Vizioli R
Recenti Prog Med; 1984 Oct; 75(10):889-901. PubMed ID: 6151219
[No Abstract] [Full Text] [Related]
6. Experimentally induced parkinsonism.
Poirier LJ; Sourkes TL
Res Publ Assoc Res Nerv Ment Dis; 1972; 50():416-33. PubMed ID: 4403656
[No Abstract] [Full Text] [Related]
7. Enzymes associated with the metabolism of catecholamines, acetylcholine and gaba in human controls and patients with Parkinson's disease and Huntington's chorea.
McGeer PL; McGeer EG
J Neurochem; 1976 Jan; 26(1):65-76. PubMed ID: 3629
[No Abstract] [Full Text] [Related]
8. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
Sajadi A; Bauer M; Thöny B; Aebischer P
J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
[TBL] [Abstract][Full Text] [Related]
9. Biochemical aspects of Parkinson's disease.
Nagatsu T
Adv Neurol; 1993; 60():165-74. PubMed ID: 8093575
[No Abstract] [Full Text] [Related]
10. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
[TBL] [Abstract][Full Text] [Related]
11. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
12. Catecholamine-metabolizing enzyme activity in the nigrostriatal system.
Francis A; Whittemore R; Jeffery DR; Pearce LB; Roth JA
Biochem Pharmacol; 1987 Jul; 36(13):2229-31. PubMed ID: 3111478
[No Abstract] [Full Text] [Related]
13. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
Darmopil S; Muñetón-Gómez VC; de Ceballos ML; Bernson M; Moratalla R
Eur J Neurosci; 2008 Feb; 27(3):580-92. PubMed ID: 18279311
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
15. Biochemical pathophysiology of Parkinson's disease.
Hornykiewicz O; Kish SJ
Adv Neurol; 1987; 45():19-34. PubMed ID: 2881444
[No Abstract] [Full Text] [Related]
16. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
17. [L-dopa-resistant Parkinson's disease with cerebral atrophy: striato-nigral degeneration?].
Dell'Aria V; Ciannella L; Melone MA
Acta Neurol Quad (Napoli); 1981; 42():212-5. PubMed ID: 7270052
[No Abstract] [Full Text] [Related]
18. Enzymatic stimulation and enzymatic inhibition in Parkinson's disease.
Nagatsu T
Acta Neurol Scand Suppl; 1993; 146():14-7. PubMed ID: 8101411
[TBL] [Abstract][Full Text] [Related]
19. [Effect of electroacupuncture scalp point-through-point therapy on the expression of tyrosine hydroxylase and dopamine transporter mRNAs in substantia nigra of Parkinson's disease model rats].
Wang S; Qi XJ; Han D
Zhongguo Zhen Jiu; 2009 May; 29(5):391-4. PubMed ID: 19489498
[TBL] [Abstract][Full Text] [Related]
20. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease.
Elsworth JD; Roth RH
Exp Neurol; 1997 Mar; 144(1):4-9. PubMed ID: 9126143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
